Onivyde based therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at how well a chemotherapy combination (Onivyde plus 5-FU and leucovorin) works for people with advanced pancreatic cancer in China. It may help your doctor understand if this treatment is effective for you, especially if you have already tried a gemcitabine-based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of pancreatic cancer that is locally advanced (has spread to nearby areas) or metastatic (has spread to other parts of the body).
- You have previously been treated with a chemotherapy drug called gemcitabine (or a regimen containing it), and your cancer kept growing despite that treatment.
- You have received at least one cycle of the study treatment: Onivyde (liposomal irinotecan) combined with 5-fluorouracil (5-FU) and leucovorin (LV), or you are about to start it.
- You are not pregnant or breastfeeding, and you are willing to sign a consent form allowing the study to use your medical data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This study watches how safe and effective a combination of chemotherapy drugs (ONIVYDE, 5-FU, and leucovorin) is for people with pancreatic cancer that has spread. It's for patients who have already tried gemcitabine without success, and the treatment is given as part of regular care, not as a separate experimental treatment.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.